Previous 10 | Next 10 |
Source: Altimmune Website Company Background: Altimmune ( ALT ) is a US biopharmaceutical company based in Gaithersburg, Maryland, USA, which focuses on developing treatments for liver disease, immune-modulating therapies, and vaccines. Altimmune has various pre-clinical to clinical ...
Inovio Pharmaceuticals ( INO +27.0% ) is up on over 80% higher volume. Shares have rallied 73% since Monday's corporate overview virtually presented by CEO Joseph Kim at H.C. Wainwright's Global Investment Conference. COVID-related highlights : More news on: Inovio Pharmac...
Gainers: Novus Therapeutics (NASDAQ: NVUS ) +162% . More news on: Novus Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Stocks on the move, , Read more ...
Tiny Vaxart (NASDAQ: VXRT) was just a penny stock back in January. Few people had heard of the company. You could buy a share for only 34 cents. And then COVID-19 hit, followed by stay-at-home orders, economic shut-downs, and the current recession. The public health crisis sent the enti...
Companies across the healthcare spectrum are involved in the fight against COVID-19. Some are working on treatments for the disease, while others have rushed to create accurate test kits that can detect traces of the SARS-CoV-2 virus in mere minutes. It's the companies working on vaccines for th...
Gainers: Immunomedics (NASDAQ: IMMU ) +100% . More news on: Immunomedics, Inc., Cassava Sciences, Inc., Vaxart, Inc., Stocks on the move, , Read more ...
Shares of Vaxart (NASDAQ: VXRT) were soaring 20.8% as of 11:22 a.m. EDT on Monday. The huge jump came after the biotech announced Food and Drug Administration clearance to begin a phase 1 clinical trial for Vaxart's oral coronavirus vaccine candidate. Vaxart reported promising pre-clinical...
Immunomedics (NASDAQ: IMMU ) +106% after Gilead to buy the company for $21B (~$88/share). More news on: Immunomedics, Inc., Cassava Sciences, Inc., China Natural Resources, Inc., , Stocks on the move, Read more ...
Vaxart's (NASDAQ: VXRT ) jumps 16% premarket after the FDA completed review of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Company's oral COVID-19 vaccine candidate. VXRT also provided an update on its COVID-19 program. ...
Recruitment for Phase 1 clinical study expected to start this month Data from ongoing hamster challenge study expected in October SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are a...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...